Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|April 10, 2024
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19Jennifer Hammond, Robert J Fountaine, Carla Yunis, et al.
Clinical Trials (London, England)|February 20, 2008
Specific barriers to the conduct of randomized trialsLelia Duley, Karen Antman, Joseph Arena, et al.
American Heart Journal|August 10, 2016
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes TrialsPaul M Ridker, Pierre Amarenco, Robert Brunell, et al.
The New England Journal of Medicine|March 18, 2017
Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabPaul M Ridker, Jean-Claude Tardif, Pierre Amarenco, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 26, 2025
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLDYasaman Vali, Anne-Marieke van Dijk, Jenny Lee, et al.
The New England Journal of Medicine|March 18, 2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsPaul M Ridker, James Revkin, Pierre Amarenco, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Nature Medicine|July 24, 2026
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging StudyMichael Pavlides, Yasaman Vali, Ferenc E Mózes, et al.
Pageof 5